文献速递眼底病与葡萄膜炎神经眼科

开槽钯-103敷贴放射治疗脉络膜黑色素瘤的12年研究:邻近、接触或环绕视神经

A 12-Year Study of Slotted Palladium-103 Plaque Radiation Therapy for Choroidal Melanoma: Near, Touching, or Surrounding the Optic Nerve.
PubMed 文献 · Am J Ophthalmol · 2018-02-01

这项回顾性介入病例系列研究纳入52例视盘附近、接触或环绕视盘的葡萄膜黑色素瘤患者,接受开槽眼敷贴放射治疗,中位随访34个月。结果显示局部肿瘤控制率达98.1%,保留眼球生存率93%,无转移生存率94%,69%患者视力保持≥20/40。

要点

  • 开槽敷贴放疗使肿瘤和2-3毫米正常组织边缘纳入靶区,局部控制率98.1%。
  • 治疗后69%患者视力保持≥20/40,视力无丢失生存期达84个月。
  • 放射性副作用包括4%继发性白内障和11%新生血管性青光眼。

核心结论

  • 开槽敷贴放射治疗实现了标准化的敷贴-肿瘤位置,使整个脉络膜黑色素瘤加上2-3毫米正常组织边缘纳入靶区。
  • 12年时,开槽敷贴放射治疗实现了高比例的局部肿瘤控制以及视力和眼球保留。

研究设计与样本

  • 回顾性介入病例系列研究,设置于纽约眼癌中心。
  • 研究人群为52例连续就诊的葡萄膜黑色素瘤患者,肿瘤邻近、接触或环绕视盘。
  • 干预为开槽眼敷贴放射治疗。
  • 主要结局指标包括视力变化、局部肿瘤控制、放射副作用、眼球挽救和全身转移。

主要发现

  • 肿瘤位于视盘周围1.5毫米内(n=8,15%)、接触视盘≤180度(n=23,44%)或环绕视盘>180度(n=21,41%)。
  • 平均随访47个月(中位34个月,范围6-146个月)。
  • 放射治疗导致肿瘤厚度平均减少41.2%。
  • 生命表分析显示,69%的患者在治疗后84个月保持视力≥20/40且视力无丢失生存。
  • 90%的患者在治疗后36个月保持视力在20/50至20/200之间且视力无丢失生存。

关键数值与推荐

  • 局部肿瘤控制(无复发)率为98.1%。
  • 无眼球摘除生存率为93%,无转移生存率为94%。
  • 69%患者视力保持≥20/40,视力无丢失生存期84个月。
  • 90%患者视力保持在20/50至20/200之间,视力无丢失生存期36个月。
  • 肿瘤厚度平均减少41.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present our 12-year experience with low-energy-photon, slotted eye plaque radiation therapy. DESIGN: Retrospective interventional case series. METHODS: Setting: The New York Eye Cancer Center. STUDY POPULATION: Fifty-two consecutive patients with uveal melanomas near, touching, or surrounding the optic disc. INTERVENTION: Slotted eye plaque radiation therapy. MAIN OUTCOME MEASURES: Change in visual acuity, local tumor control, radiation side effects, eye salvage, and systemic metastases. RESULTS: Tumors were peripapillary within 1.5 mm of the optic disc (n = 8, 15%), juxtapapillary touching ≤180 degrees (n = 23, 44%), or circumpapillary >180 degrees and encircling the disc (n = 21, 41%). Mean follow-up was 47 months (median 34 months, range 6-146 months). Radiation induced a mean 41.2% reduction in tumor thickness. Life table analysis showed that 69% of patients retained their visual acuities ≥ 20/40 and had a vision loss-free survival 84 months after treatment. Also, 90% of patients retained their visual acuity between 20/50 and 20/200 and had a vision loss-free survival 36 months after treatment. Slotted plaque brachytherapy was associated with 4% secondary cataract, 11% neovascular glaucoma, and no dry eye or eyelash loss. Local tumor control (no recurrence) was achieved in 98.1% of patients. Life table analysis showed an overall enucleation-free survival of 93% and metastasis-free survival of 94%. CONCLUSIONS: Slotted plaque radiation therapy provided a normalized plaque-tumor position, such that the entire choroidal melanoma plus a 2- to 3-mm free margin of normal-appearing tissue was included in the targeted zone. At 12 years, slotted plaque radiation therapy resulted in high rates of local tumor control and vision and eye retention.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Maheshwari A, Finger PT. A 12-Year Study of Slotted Palladium-103 Plaque Radiation Therapy for Choroidal Melanoma: Near, Touching, or Surrounding the Optic Nerve. Am J Ophthalmol. 2018. PMID: 29409899. doi:10.1016/j.ajo.2018.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。